Organization Overview
Historical Acquisition Tree
Key: Repligen Corporation (0) Acquired (1)
eflapegrastim (Rolvedon) (2022 NDA)
Key: Repligen Corporation (1) Acquired (20)
carboplatin (paraplatin) (4 trials)
cisplatin (platinol) (2 trials)
cyclophosphamide (cytoxan) (7 trials)
eflapegrastim (Rolvedon) (5 trials)
Filgrastim (neupogen) (6 trials)
gemcitabine (gemzar) (2 trials)
ibritumomab tiuxetan (Zevalin) (9 trials)
Key: Repligen Corporation (1) Acquired (42)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (2 trials)
autologous hematopoietic stem cells (2 trials)
belinostat (beleodaq) (12 trials)
bendamustine (treanda) (3 trials)
bortezomib (velcade) (2 trials)
clofarabine (clolar) (1 trial)
cyanocobalamin (berocca) (8 trials)
cyclosporine (sandimmune) (1 trial)
Key: Repligen Corporation (2) Acquired (13)
Autistic Disorder (Phase 3)
Bipolar Disorder (Phase 2)
Compulsive Personality Disorder (Phase 2)
Depression (Phase 2)
Depressive Disorder (Phase 2)
Disease (Phase 2)
Mitochondrial Diseases (Phase 1)
Multiple Sclerosis (Phase 1)
Multiple Sclerosis, Relapsing-Remitting (Phase 1)
Obsessive-Compulsive Disorder (Phase 2)
Pancreatic Neoplasms (Phase 1)
Pancreatitis (Phase 3)
Schizophrenia (Phase 2)
Sclerosis (Phase 1)